Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Marianna Zahurak et al.|New England Journal of Medicine|2018Cited by 2.1k
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588
Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell lineElizabeth Chang, Richard J. Battafarano|Journal of Thoracic and Cardiovascular Surgery|2010Cited by 16